**Chapter 11**

*Advances in Precision Medicine Oncology*

[99] Wildiers H, Jurcut R, Ganame J, Herbots L, Neven P, De Backer J, et al. A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients. Critical reviews in oncology/hematology. 2008 Aug

Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis. Cell death &

[106] Ma ZG, Dai J, Yuan YP, Bian ZY, Xu SC, Jin YG, et al. T-bet deficiency attenuates cardiac remodelling in rats. Basic Research in Cardiology. 2018 May

disease. 2015 May;6(5):e1754-.

1;**113**(3):19

1;**67**(2):133-138

[100] Arnold JM, Howlett JG, Ducharme A, Ezekowitz JA, Gardner MJ, Giannetti N, et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure–2008 update: best practices for the transition of care of heart failure patients, and the

[101] Culty M, Nguyen HA,

15;**116**(4):1055-1062

15;**52**(16):4379-4384

recognition, investigation and treatment of cardiomyopathies. Canadian Journal of Cardiology. 2008 Jan 1;**24**(1):21-40

Underhill CB. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. The Journal of cell biology. 1992 Feb

[102] Lewis AD, Lau DH, Durán GE, Wolf CR, Sikic BI. Role of cytochrome

[103] Baldwin A, Huang Z, Jounaidi Y, Waxman DJ. Identification of novel enzyme–prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Archives of biochemistry and biophysics. 2003 Jan 1;**409**(1):197-206

P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. Cancer research. 1992 Aug

[104] Michael JB, Tannock IF. Lysosomes, lysosomal enzymes and cancer. Advances in Cancer Research.

[105] Roca-Alonso L, Castellano L, Mills A, Dabrowska AF, Sikkel MB, Pellegrino L, Jacob J, Frampton AE, Krell J, Coombes RC, Harding SE.

1993;**60**:269-291

**188**
